CROSSJECT provides updates on the EUA filing of ZEPIZURE®
GlobeNewswire·2025-05-07 05:30
Press Release CROSSJECT provides updates on the EUA filing of ZEPIZURE® CROSSJECT and its EUROFINS CDMO partner successfully completed the aseptic filling of all ZEPIZURE® registration batches and anticipate the delivery of the last manufacturing data needed for U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) submission in June 2025.CROSSJECT started the final regulatory activities for the ZEPIZURE® dossier submission under EUA.CROSSJECT began manufacturing EUA batches, intended as ...